Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
about
Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a miceAgile delivery of protein therapeutics to CNSEffects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting.Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.Haemophilia A: from mutation analysis to new therapies.Development and characterization of lipidic cochleate containing recombinant factor VIII.Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administrationMechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice.O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicityInfluence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A micePassive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a miceImmunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A miceDelivery of therapeutic proteins.Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model.Phosphatidylserine is not just a cleanup crew but also a well-meaning teacher.
P2860
Q33469732-DCFCEC42-9D21-41DE-8E9D-B91DDFA94D59Q33954639-C6815619-BD42-4E44-8755-6C6EC1722B8EQ34079647-80EFFD9C-8FC6-4EEA-9183-02E70E648D85Q34099771-DA65FA71-F1AD-42B9-B76D-E2F1A8363C61Q34678914-9F2119C3-9013-49B1-A0CD-E44D877A708FQ34688731-D9264468-1AF8-4FD6-8803-D7C0C09B20FCQ34744656-B72CA4BA-AE15-4B3F-B035-68BC3A25E705Q35498838-34196256-C615-4991-815D-B4720A3F8E61Q35793113-9781B9E6-A22E-4F8A-B7A7-03A2561C233BQ36148386-39ADF2BE-48B8-4B76-9DB5-178D4ABA42CBQ36267136-3D8DB3C3-2B46-491B-8015-600FD2D38573Q36276649-94AB9EF5-4F14-4679-9914-0750DD53C76FQ36707550-F9C3F939-ED70-4472-B4B1-8425FFD3FE58Q36928899-449F7555-C7E4-4B10-8240-CE289F564298Q36950100-BAA34EB5-469C-417D-9500-DB80C00FB5FEQ36950922-39D55F4B-8C3F-4026-8A4A-4F1E8C37558EQ36951646-428BAF93-D3F3-41F1-97A0-D0545ADD23BAQ36951675-B7D62E5B-455F-456D-8E14-F16A0B4A52EEQ36951699-93167B80-775A-4DA9-AD27-ABA2AA742409Q37174443-CA1CF69E-C00B-4192-87A4-010D0EF49346Q37207756-30B94100-886E-40C8-987B-A5D589E22374Q37485765-1A194298-86A5-4B26-9FE7-5662CCEE1D7AQ37668486-B14A5163-244F-42CF-B0E0-C3EE7B5F7A11Q39527140-F6A45087-8227-4DA0-A20C-DC376F7EC0B9Q41651439-92E43153-36F1-411B-9292-4A622A501A0DQ52591717-552B305A-0AB9-4D0A-BA0D-D11669D95A2E
P2860
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lower inhibitor development in ...... II-O-phospho-L-serine complex.
@en
type
label
Lower inhibitor development in ...... II-O-phospho-L-serine complex.
@en
prefLabel
Lower inhibitor development in ...... II-O-phospho-L-serine complex.
@en
P2093
P2860
P921
P356
P1476
Lower inhibitor development in ...... II-O-phospho-L-serine complex.
@en
P2093
Haig H Kazazian
Karthik Ramani
Rita Sarkar
Sathyamangalam V Balasubramanian
Vivek S Purohit
P2860
P304
17593-17600
P356
10.1074/JBC.M500163200
P407
P577
2005-02-23T00:00:00Z